Category: ATG-010
Shots: The NMPA has approved a P-I/II SWATCH dose-escalation & dose-expansion study that evaluates the safety, tolerability, and preliminary efficacy of selinexor in combination with the R2 regimen of lenalidomide + rituximab for rrDLBCL and rriNHL who are not eligible for HDC or ASCT. The study was conducted at 10 centers across China The 1EPs […]
Shots: The NMPA has approved an IND application for P-Ib MATCH, dose-escalation study to evaluate the safety of ATG-008 + ATG-010 in patients with r/r DLBCL. The study will be conducted at ten centers across China, including its primary trial center at Sun Yat-Sen University Cancer Center The 1EPs of the study include MTD and […]
Shots: The NDA is based on STORM and SADAL studies. The P-IIb STORM study involves assessing of ATG-010 + low-dose dexamethasone in patients with rrMM prior treated with at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 mAb The P-II SADAL study […]